VolitionRx milestone payment ‘important step forward,’ says EF Hutton

EF Hutton keeps a Buy rating on VolitionRx with a $4.50 price target after the company received a $13M milestone payment from Heska. The payment “marks an important step forward” in the commercialization of canine cancer tests and demonstrates the commitment following the merger of Heska and Mars Incorporated, the analyst tells investors in a research note. Shares of VolitionRx are up 37% to 98c to afternoon trading.